Antiglucocorticoid Augmentation of antiDepressants in Depression
Antiglucocorticoid Augmentation of antiDepressants in Depression
Depression is one of the most common mental health problems, with at least one in six adults
 suffering from this at some time in their life. It can become long-lasting and frequently
 recurs. Depression has a large negative impact on quality of life of patients and their
 carers and it has also been shown to be one of the leading causes of working age adults
 receiving disability payments in the UK. The need for improved treatment has been recognised
 by the Department of Health and others. Improvements in drug treatments are therefore
 required. There has been recent increased understanding of some of the causes of the frequent
 lack of complete response seen with antidepressants. The stress hormone, cortisol, is often
 elevated or poorly controlled in depression and there is laboratory and clinical research to
 show that this hormonal change reduces the benefits from antidepressants with associated poor
 outcome and memory problems. Recently it has been shown in small studies that giving
 treatments that reduce cortisol or block its harmful effects for between 1 and 3 weeks
 overcome these negative consequences. Our group is particularly interested and experienced in
 this topic. The investigators plan to study a drug that decreases cortisol levels in people
 who have not recovered with standard antidepressants so that the investigators can find out
 the usefulness of this treatment (compared with placebo (dummy tablet)) in day to day life as
 well as checking closely for side-effects (the initial studies have shown that the particular
 drug the investigators wish to study (metyrapone) has few side effects). The investigators
 will also measure cortisol and see if its level can tell us which people do best with this
 treatment. The investigators will carry out this study in 3 centres across the UK. The
 investigators will carry out some additional tests of specific sorts of memory and decision
 making and also do this while scanning the brain (in a painless test). The results of these
 tests, along with tests of brain wave patterns, should help us understand more fully how this
 new treatment is working and who responds best to it. The study will help us find out if this
 drug should be used more widely for people not responding to standard treatments and will
 also lead on to the development of other new treatments with an anti-cortisol effect to help
 tackle the major problem of poor outcome from depression.
Patient Inclusion Criteria:

 1. Depression Severity: Hamilton Depression Rating Scale (HDRS17) score ≥18, consistent
 with a moderate to severe episode. The stability of the patient's clinical state will
 also be assessed at week 0. A repeat HDRS17 score at time 0 is required ≥18 or
 greater.

 2. Treatment refractoriness: assessed using the Massachusetts General Hospital (MGH)
 staging method. This defines minimum effective doses of all currently-available
 antidepressants and an "adequate trial" as being for at least six weeks. For the trial
 to be considered a "failure", it must have been considered by the clinical team to
 have been ineffective rather, than the drug not having been taken or tolerated.
 Patients must have failed to have responded to at least their second trial of an
 antidepressant. This equates to a minimum score of two on MGH staging. The maximum MGH
 score for inclusion in the study will be 10. A UK study showed mean MGH scores in
 primary care patients of less than one, in secondary care mental health settings of
 around five and of 11 in a population of patients referred to a tertiary centre (Dr D
 Christmas, Dundee, Personal Communication).

 3. Current antidepressant treatment: patients must be taking monotherapy or combination
 antidepressant therapy which includes a serotonergic drug (an SSRI, a tertiary amine
 tricyclic, venlafaxine, duloxetine or mirtazapine). They must not be on noradrenergic
 antidepressant monotherapy (e.g. with lofepramine, imipramine or reboxetine). At the
 point of randomisation, patients must have been on their current antidepressant
 medication, at the current dose, for a minimum of four weeks.

 4. Age: 18-65. For the mechanistic sub-studies the patients upper age limit is 60.

 Healthy Control Inclusion Criteria:

 1. Aged 18-60.

 2. Currently psychiatrically well, confirmed through SCID interview. HDRS17 score of ≤5,
 and no current psychotropic medication.

 3. No past history of psychiatric illness, as revealed by SCID interview, or requiring
 any treatment (formal psychotherapy or psychotropic medication).

 4. No first degree family history of psychiatric illness.

 Patient Exclusion Criteria:

 1. Any other DSM IV Axis I disorder other than an anxiety disorder unless the depressive
 episode is considered to be secondary to the anxiety disorder, confirmed using the
 Structured Clinical Interview for DSM (SCID).

 2. Physical co-morbidity which would render the use of Metyrapone inappropriate,
 including untreated hypothyroidism, disorders of steroid production, current, severe
 cardiac failure, current, severe or frequent angina, current renal failure or
 myocardial infarction within the last year.

 3. Pregnancy, determined by history and, if indicated, urine pregnancy test.

 4. Mothers who are breastfeeding.

 5. Use of concomitant medication that would interfere, in a pharmacodynamic or
 pharmacokinetic manner, with Metyrapone.

 6. Dependence on alcohol or other drug in the past 12 months, and/or current harmful use
 of alcohol or other drug.

 7. Recently having taken part in another research study that could interfere with the
 results of this one.

 Healthy Control Exclusion Criteria:

 1. Any physical ill health which would render the use of Metyrapone inappropriate,
 including untreated hypothyroidism, disorders of steroid production, current, severe
 cardiac failure, current, severe or frequent angina, current renal failure, or
 myocardial infarction within the last year. NOTE: healthy controls are NOT treated
 with Metyrapone.

 2. Pregnancy, determined by history and, if indicated, urine pregnancy test.

 3. Mothers who are breastfeeding.

 4. Use of any medication that would interfere, in a pharmacodynamic or pharmacokinetic
 manner, with Metyrapone.

 5. Dependence on alcohol or other drug in the past 12 months, and/or current harmful use
 of alcohol or other drug.

 6. Presence of any metal implants or foreign bodies such as from a surgical implant,
 accident or injury [this criteria only applies to those undergoing the fMRI scans -
 this is all 30 healthy subjects recruited in the North West (NW)and 15 of the 25
 recruited in the North East (NE)].

 7. Recently having taken part in another research study that could interfere with the
 results of this one.